Tumor heterogeneity is a major barrier to effective cancer diagnosis and treatment. We recently identified cancer-specific differentially DNA-methylated regions (cDMRs) in colon cancer, which also distinguish normal tissue types from each other, suggesting that these cDMRs might be generalized across cancer types. Here we show stochastic methylation variation of the same cDMRs, distinguishing cancer from normal tissue, in colon, lung, breast, thyroid and Wilms' tumors, with intermediate variation in adenomas. Whole-genome bisulfite sequencing shows these variable cDMRs are related to loss of sharply delimited methylation boundaries at CpG islands. Furthermore, we find hypomethylation of discrete blocks encompassing half the genome, with extreme gene expression variability. Genes associated with the cDMRs and large blocks are involved in mitosis and matrix remodeling, respectively. We suggest a model for cancer involving loss of epigenetic stability of well-defined genomic domains that underlies increased methylation variability in cancer that may contribute to tumor heterogeneity.
Cancer is generally viewed as over 200 separate diseases of abnormal cell growth controlled by a series of mutations but also involving epigenetic non-sequence changes in the same genes 1 . DNA methylation at CpG dinucleotides has been studied extensively in cancer, with hypomethylation or hypermethylation reported at some genes, and global hypomethylation has been ascribed to normally methylated repetitive DNA elements. Until now, cancer epigenetics has focused on high-density CpG islands, gene promoters or dispersed repetitive elements 2,3 .
Here we took a different and more general approach to cancer epigenetics. This approach is based on our recent observation of frequent methylation alterations in colon cancer of regions of lower CpG density near islands, termed shores, as well as the observation that these cancer-specific differentially methylated regions, or cDMRs, correspond largely to the same regions that show DNA methylation variation among normal spleen, liver and brain, or tissue-specific DMRs (tDMRs) 4 . Furthermore, cDMRs are highly enriched among regions differentially methylated during stem cell reprogramming of induced pluripotent stem (iPS) cells 5 . We thus reasoned that the very same sites might be generalized cDMRs, as they are involved in normal tissue differentiation but show aberrant methylation in at least one cancer type (colon).
We tested this hypothesis by designing a semiquantitative custom Illumina array for methylation analysis of 151 cDMRs consistently altered across colon cancer and analyzed these sites in 290 samples, including matched normal and cancer samples from colon, breast, lung, thyroid and Wilms' tumor. We were surprised to discover that almost all of these cDMRs were altered across all cancers tested. Specifically, the cDMRs showed increased stochastic variation in methylation level within each tumor type, suggesting a generalized disruption of the integrity of the cancer epigenome. To investigate this idea further, we performed genome-scale bisulfite sequencing of three colorectal cancers, the matched normal colonic mucosa and two adenomatous polyps. These experiments revealed a notable loss of methylation stability in colon cancer, which involved CpG islands and shores, and large (up to several Mb) blocks of hypomethylation affecting more than half of the genome, with associated stochastic variability in gene expression, which we suggest could provide an epigenetic mechanism for tumor heterogeneity.
RESULTS

Stochastic variation in DNA methylation across cancer types
We sought to increase the precision of DNA methylation measurements over our previous tiling array-based approach, termed CHARM 6 , analyzing 151 colon cDMRs 4 . We designed a custom nucleotide-specific Illumina bead array of 384 probes covering 139 regions 7 . We studied 290 samples, including cancers from colon, lung, Increased methylation variation in epigenetic domains across cancer types breast, thyroid and Wilms' tumor, with matched normal tissues to 111 of these 122 cancers, along with 30 colon premalignant adenomas and 27 additional normal samples (Online Methods). To minimize the risk of genetic heterogeneity arising from sampling multiple clones, we purified DNA from small (0.5 cm × 0.2 cm) sections verified by histopathologic examination.
Cluster analysis of the DNA methylation values revealed that the colon cancer cDMRs largely distinguished cancer from normal cells for each tumor type ( Supplementary Fig. 1) . The increased acrosssample variability in methylation within the cancer samples of each tumor type compared to normal was even more striking than the differences in mean methylation. We therefore computed across-sample variance within normal and cancer samples in all five tumor and normal tissue types at each CpG site. Although we selected these CpGs sites for differences in mean values in colon cancer, the great majority showed greater variance in cancer than normal in each tissue type ( Fig. 1a-e ), even after accounting for differences in variability expected from mean shifts according to a binomial distribution model of methylation measurements ( Supplementary Fig. 2 ). This increase was statistically significant (P < 0.01 using an F test) for 81%, 92%, 81%, 70% and 80% of the CpG sites in colon, lung, breast, thyroid and Wilms' tumor, respectively. Furthermore, 157 CpG sites had statistically significant increased variability in all cancer types tested. We found this increased stochastic variation in CpG islands, CpG island shores and regions distant from islands ( Fig. 1a-e ). These data suggest a potential mechanism of tumor heterogeneity, namely increased stochastic variation of DNA methylation in cancers compared to normal cells, within each tumor type tested (see the Discussion section).
We ruled out increased cellular heterogeneity and the age of the affected individual as artifactual causes for methylation heterogeneity in cancer samples (Supplementary Figs. 3,4 ). Furthermore, there was no difference in methylation hypervariability when comparing five high-copy-variation colon cancers to five low-copy-variation Wilms' tumors ( Supplementary Fig. 5a,b) , arguing against genetic heterogeneity as a cause of methylation hypervariability. Similarly, seven Wilms' tumors without aberrant p53 expression by immunohistochemistry showed similar methylation hypervariability to seven colon tumors with positive staining, which is a marker of chromosomal instability (Supplementary Fig. 6 ).
The loci where we observed increased variability in cancer were also able to distinguish the five normal tissues from each other, but this is a mean shift rather than a variation shift, which was apparent from a cluster analysis ( Supplementary Fig. 7) . Notably, this was the case even when we only used the 25 most variable sites in cancer ( Fig. 1f) . This result reinforces the concept of a biological relationship between normal tissue differentiation and stochastic variation in cancer DNA methylation.
To determine if the increased variability is a general property of cytosine methylation in cancer or a specific property of the CpGs selected for our custom array, we used as a control a publicly available methylation dataset comparing colorectal cancer to matched normal mucosa on the Illumina HumanMethylation 27K BeadChip array. In this dataset, we found that only 42% of the sites showed a statistically significant increase in methylation variability compared to 81% in the custom array (P < 0.01), confirming the specificity of the cancer DMRs included in our custom array. Increased stochastic A r t i c l e s variation was more common in CpGs far from islands (57%) than in shores (44%) or islands (31%), contrasting the relative representation of these locations on the 27K array, which breaks down as distal to islands (26.4%), shores (31.6%) and islands (42%) (Online Methods). This result suggested that something other than relationship to CpG islands might be defining the largest fraction of sites of altered DNA methylation in cancer.
Hypomethylation of large DNA methylation blocks in colon cancer
The methylation stochasticity described above appears to be a general property of cancer, affecting cDMRs in both island and non-island regions, in all five cancer types tested. To investigate this apparent universal loss of DNA methylation pattern integrity in cancer and analyze lower CpG abundance regions not examined by array-based methods, we performed shotgun bisulfite genome sequencing on three colorectal cancers and the matched normal colonic mucosa using the ABI SOLiD platform. We wanted to obtain methylation estimates with enough precision to detect differences of 10% methylation. Because we used a local likelihood approach, which aggregated information from neighboring CpGs and combined data from three biological replicates, we determined that 4× coverage would suffice to estimate methylation values at this precision with a standard error of at most 3% (Online Methods). We therefore obtained between 12.5 and 13.5 Gb for each sample, providing ~5× coverage for each CpG after quality control filtering (Online Methods) and alignment (Supplementary Table 1 ). To verify the accuracy of the methylation values obtained by our approach, we performed capture bisulfite sequencing on the same six samples for 39,262 regions yielding 39,300-125,600 CpG with >30× coverage ( Supplementary Table 2 ), with correlations of 0.82-0.91 between our local likelihood approach and capture sequencing, a remarkable agreement, as the experiments were performed in different laboratories using different sequencing platforms and protocols. Examination of individual loci showed that our methylation estimates closely track the high-coverage capture data ( Supplementary Fig. 8 ).
We also performed traditional bisulfite pyrosequencing, further confirming the accuracy of our approach (Supplementary Fig. 9 ). Sequencing analysis revealed the presence of large blocks of contiguous hypomethylation in cancer compared to normal cells ( Fig. 2a,b) . We identified 13,540 such regions of length 5 kb to 10 Mb ( Table 1 and Supplementary Table 3 ). The across-cancer average hypomethylation throughout the blocks was 12-23%. Remarkably, these hypomethylated blocks in cancer corresponded to more than half of the genome, even after accounting for the number of CpG sites within the blocks ( Table 1) , and may include small hypermethylated regions. We also noted the existence of a small fraction (3%) of hypermethylated blocks in cancer ( Table 1 and Fig. 2a,b) . A histogram of the smoothed methylation values shows the shift in distribution of global DNA methylation (Fig. 2c) . The predominant change in block methylation in cancer was a loss in the abundant compartment of intermediate methylation levels (with a mean of 73% for all samples) to substantially lower levels (50-61%) ( Fig. 2d) .
These blocks are common across all three cancers. An analysis of the tumors individually compared to a normal profile showed consistent block boundary locations ( Fig. 2, Supplementary Fig. 10 and Online and cancer samples (red). Note that although the normal and cancer distributions are similar outside the blocks, within the blocks, methylation values for cancer show a general shift. (e) Distribution of methylation differences between cancer and normal samples stratified by inclusion in repetitive DNA and blocks. Inside the blocks, the average difference was ~20% in both in repeat and non-repeat areas. Outside the blocks, the average difference was ~0% in repeat and non-repeat areas, indicating that blocks rather than repeats account for the observed differences in DNA methylation. The boxes show the 25% quantile, the median and the 75% quantile, and each whisker has a length of 1.5 times the interquartile range.
Methods). These blocks were not driven by copy number variation, as the location of the latter was not consistent across subjects, which is in contrast to the consistent block boundaries ( Supplementary  Fig. 11a,b) , and the methylation difference estimates provided by our statistical approach did not correlate with copy number values ( Supplementary Fig. 11c ).
Global hypomethylation in cancer 8 is attributed to the presence of normally methylated repetitive elements 9 and may be relevant to colon cancer, as LINE-1 element hypomethylation is associated with worse prognosis in colon cancer 10 . We observed that in normal tissues, repetitive elements were more methylated than non-repetitive regions (76% versus 66%). To determine whether such repetitive elements were responsible for the block hypomethylation, we compared differences in methylation levels inside and outside repeat elements (Online Methods) both inside and outside blocks. Most of the global hypomethylation was caused by hypomethylated blocks ( Fig. 2e) and not the presence of repetitive elements. As repetitive elements are slightly enriched in blocks (odds ratio (OR) = 1.4), much of the apparent repeat-associated methylation may in fact be caused by blocks. This result does not exclude repeat-associated hypomethylation, as not all repeats were mappable. However, 57% of L1 elements, 94% of L2 elements, 95% of MIR sequences and 18% of Alu elements were covered by our data ( Supplementary Table 4 ) and did not show repeat-specific hypomethylation (Supplementary Fig. 12 ). Note that it is possible that Alu sequences not covered by our data are somehow more hypomethylated than the covered Alu sequences and thus may contribute to global hypomethylation.
Researchers from a previous study performed bisulfite sequencing analysis of the H1 human embryonic stem cell line compared to the IMR90 fibroblast line and identified large regions of the genome that are less methylated in fibroblast cells than in embryonic stem cells, which are referred to as partially methylated domains (PMDs) 11 . The intermediate methylation level regions we identified above largely coincided with the PMDs, containing 85% of CpGs inside PMDs (OR = 6.5, P < 2 × 10 −16 ; Supplementary Table 5 ). We previously described large organized chromatin lysine modifications, or LOCKs, genome wide in normal mouse cells that are associated with both constitutive and tissue-specific gene silencing 12 . We mapped LOCKs in primary human cells (Online Methods). Remarkably, 89% of the LOCKs were contained within the blocks (OR = 6.8, P < 2 × 10 −16 ). LOCKs are also known to overlap with nuclear lamina-associated domains or LADs 12 . Approximately 83% of the LADs were also contained within the blocks (OR = 4.9, P < 2 × 10 −16 ). In addition, DNase I hypersensitive sites, a structural signal for regulatory regions 13 , were enriched within 1 kb of block boundaries and small DMRs (P < 2 × 10 −16 for both). Thus the large hypomethylated blocks we identified in cancer correspond to a genomic organization identified in normal cells by several complementary methods. Note that although the PMDs and our hypomethylated blocks largely overlap, we later show significant differences in gene expression in cancer between non-overlapping blocks and PMDs.
We observed a relationship between the 157 CpGs that are hypervariable across all cancer types identified by our custom array and the hypomethylated blocks identified by whole-genome bisulfite sequencing. We found that 63% of the hypomethylated hypervariable CpGs were within hypomethylated blocks and 37% of the hypermethylated hypervariable CpGs were within the rare hypermethylated blocks. In contrast, hypomethylated and hypermethylated CpGs, respectively, from the control HumanMethylation 27K array that were not hypervariable in cancer were enriched only 13% and 1.5% in the hypomethylated and hypermethylated blocks, respectively, and showed high statistical significance for enrichment of hypervariably methylated CpGs in blocks (P < 2 × 10 −16 ; Supplementary Table 6 ).
Small DMRs involve loss of methylation boundary stability
We developed a statistical algorithm (Online Methods) for detecting DNA methylation changes in regions smaller than the blocks (≤5 kb). Our analysis of biological replicates was critical, as we found that regions showing across-subject variability in normal samples would be easily confused with DMRs if only one cancer-normal pair was available ( Supplementary Fig. 13 ). Methylation measurements in these smaller regions were in good agreement with measurements from our previous CHARM-based microarray analysis 4 (Supplementary Fig. 14) . We refer to these as small DMRs to distinguish them from the large (>5 kb) differentially methylated blocks described above. The increased comprehensiveness of sequencing over CHARM and other published array-based analyses allowed us to detect more small DMRs than previously reported; we detected 5,810 hypermethylated and 4,315 hypomethylated small DMRs ( Supplementary Table 7 ). We also confirmed our previous finding 4 that hypermethylated cDMRs are enriched in CpG islands, whereas hypomethylated cDMRs are enriched in CpG island shores ( Table 1) . Sequencing also showed that the ratio of unmethylated to methylated islands is approximately 2:1 in normals; for both types of islands, there is an approximately 20% change methylation state in cancers ( Table 2 and Supplementary Table 8 ).
The most striking and consistent characteristic of small DMR architecture was a shift in one or both of the DNA methylation boundaries of a CpG island out of the island and into the adjacent region ( Fig. 3a) or into the interior of the island (Fig. 3b) . Boundary shifts into a As described in the text, loss of boundary DMRs were associated with increase of methylation in the CpG island and a decrease of methylation in the adjacent shore. We score these as a single event and classify them here since there are more CpGs in the islands than in the shores. N/A, not applicable, as only ref genome assembly hg19 was used.
A r t i c l e s islands would appear as hypermethylated islands on array-based data, whereas boundary shifts out of islands would appear as hypomethylated shores.
The second most frequent category of small DMRs involved loss of methylation boundaries at CpG islands. For example, we defined many hypermethylated cDMRs in normal samples by unmethylated regions surrounded by highly methylated regions. In cancer, these regions showed stable methylation levels of approximately 40-60% throughout (Table 1 and Fig. 3c ). These regions with loss of methylation boundaries largely correspond to what are classified as hypermethylated islands in cancer.
We also found hypomethylated cDMRs that arose de novo in highly methylated regions outside of blocks, which we call novel hypomethylated DMRs, usually corresponding to CpG-rich regions that were not conventional islands ( Table 1) . Here, regions in which normal colon tissue was 75-95% methylated dropped to lower levels (20-40%) in cancer (Fig. 3d) . In summary, in addition to the hypomethylated blocks, we found 10,125 small DMRs, 5,494 of which clearly fell in three categories: shifts of methylation boundaries, loss of methylation boundaries and novel hypomethylation. Note that not all small DMRs followed a consistent pattern across all three sample pairs and were therefore not classified ( Table 1) .
Colon adenomas intermediate between normal and cancer tissue
Using multidimensional scaling of the methylation values measured with the custom array in colon samples, we noticed that normal samples clustered tightly together, in contrast to the cancer sample, which were dispersed (Fig. 4a) . This is consistent with the observed increase in methylation variability in cancer described earlier. We analyzed 30 colon adenomas on the custom array and found that they were intermediate in both variability within samples and distance to the cluster of normal samples (Fig. 4a) .
We subsequently performed whole-genome bisulfite sequencing on two of these adenomas: a premalignant colon adenoma with a relatively small methylation-based distance to the normal colons and an adenoma with a large methylation-based distance to the normal colons, similar to the cancer samples. We computed the average methylation levels over each block from each sequenced sample and computed pairwise Euclidean distances between samples using these values. These measurements from the hypomethylated blocks confirmed the characteristic observed in the array data: there was genome-wide increased variability in cancer compared to normal tissue, with adenomas showing intermediate values (Fig. 4) .
Cell cycle gene expression and small DMRs
Whole-genome analysis has shown an inverse relationship between gene expression and methylation, especially at transcriptional start sites 14 . To study this relationship in small DMRs, we obtained public microarray gene expression data from cancer and normal colon samples (Online Methods) and compared it to results from our sequencing data. We mapped 6,869 genes to DMRs within 2 kb of the gene's transcription start site and observed the expected inverse relationship between DNA methylation and gene expression (r = −0.27, P < 2 × 10 −16 ; Supplementary Fig. 15 ).
We examined the inverse relationship between methylation and gene expression for each category of small DMRs separately and noticed that the strongest relationship for hypomethylated shores is caused by methylation boundary shifts ( Supplementary Table 9 ). We performed gene ontology enrichment analysis 15 for differentially expressed genes (false discovery rate <0.05) comparing those associated with hypomethylated boundary shifts to the other categories. Categories ( Supplementary Table 10 ) were strongly enriched for mitosis and the cell-cycle-related genes CEP55, CCNB1, CDCA2, PRC1, CDC2, FBXO5, AURKA, CDK1, CDKN3, CDK7 and CDC20B, among others ( Supplementary Table 11 ).
Increased gene expression variation in blocks and DMRs
We compared across-subject methylation variability levels between cancer and normal samples within the blocks and found a striking similarity to the cancer methylation hypervariability found with the custom array ( Fig. 1a-e compared to Supplementary Fig. 16 ).
To study the relationship to gene expression in colon cancer, we obtained public gene expression data from cancer and normal samples (Online Methods). Genes in the blocks were generally silenced (80% silenced genes in all samples) both in normal and cancer samples. Of the genes consistently transcribed in normal tissue, albeit at low levels, 36% were silenced in blocks in cancers, compared to the 15% expected by chance. This is consistent with other reports in the literature 16 .
In a finding more striking than the subtle differences in gene silencing, we found substantial enrichment of genes with increased expression variability in cancer compared to normal samples in the hypomethylated blocks. First, we ruled out that this observed increased variability was caused by the potential high cellular heterogeneity of cancer (Supplementary Fig. 17a ). Then, we noticed a clear and statistically significant association between increased variability in expression of a gene and its location within a hypomethylated block (Supplementary Fig. 17b ). For example, 26 of the 50 genes with the largest increase in expression variability were inside the blocks, 52% compared to the 17% expected by chance (P = 3 × 10 −9) . Expression levels for 25 of these genes had an interesting pattern: although never expressed in normal samples, they showed stochastic expression in cancer ( Fig. 5 and Supplementary Fig. 18 ). For example MMP3, MMP7, MMP10, SIM2, CHI3L1, STC1 and WISP (described in the Discussion section) were expressed in 96%, 100%, 67%, 8%, 79%, 50% and 17% of the cancer samples, respectively, but were never expressed in normal samples ( Supplementary Table 12 ).
Functional differences between blocks and PMDs
As noted above, the hypomethylated blocks we observed substantially overlapped the PMDs previously reported in a fibroblast cell line 11 . We examined the genomic regions of no overlap between blocks and PMDs to identify potential functional differences between them. We grouped them into two sets: (i) regions within the hypomethylated . Standardization was performed using the gene expression barcode. Genes with standardized expression values below 2.54 or the 99.5 th percentile of a normal distribution (horizontal dashed line) were determined to be silenced by the barcode method 26 . Vertical dashed lines separate the values for the different genes. Note there is consistent expression silencing in normal samples compared to hypervariable expression in cancer samples. A similar plot drawn from an alternative GEO dataset is shown in supplementary Figure 18 . A r t i c l e s blocks but not in the PMDs (B+P−) and (ii) regions within the PMDs but not in the hypomethylated blocks (B−P+). We obtained microarray gene expression data from fibroblast samples (Online Methods) and, as expected, the genes in the fibroblast PMDs were relatively silenced in the fibroblast samples (P < 2 × 10 −16 ). Furthermore, genes that were silenced in the fibroblast samples and consistently expressed in normal colon were enriched in the B-P+ regions (OR = 3.2, P < 2 × 10 −16 ), whereas genes consistently silenced in colon and consistently expressed in fibroblast samples were enriched in the B+P− regions (OR = 2.8, P = 0.0004). Finally, the 50 hypervariable genes described above were markedly enriched in the B+P− regions (P = 0.00013), yet they showed no enrichment in the B−P+ regions. These results suggest that hypervariable gene expression in colon cancer may be related to their presence in hypomethylated blocks.
DISCUSSION
In summary, we show that colon cancer cDMRs are generally involved in the common solid tumors of adulthood (lung, breast, thyroid and colon cancer) and the most common solid tumor of childhood (Wilms' tumor), with tight clustering of methylation levels in normal tissues and marked stochastic variation in cancers. Efforts to exploit DNA methylation for cancer screening focus on identifying narrowly defined cancer-specific profiles 17 . Our data suggest future efforts might instead be directed at defining the cancer epigenome as the departure from a narrowly defined normal profile. Notably, two-thirds of all methylation changes in colon cancer involve hypomethylation of large blocks, with consistent locations across samples, comprising more than half of the genome. The functional relevance is supported by the fact that genes in colon blocks not in fibroblast blocks tend to be silenced in colon and not in fibroblasts and vice versa.
The most variably expressed genes in cancer are enriched in the blocks and involve genes associated with tumor heterogeneity and progression, including three matrix metalloproteinase genes, MMP3, MMP7 and MMP10 (ref. 18) , and a fourth gene, SIM2, which acts through metalloproteinases to promote tumor invasion 19 . Another gene, STC1, helps mediate the Warburg effect of reprogramming tumor metabolism 20 . CHI3L1 encodes a secreted glycoprotein associated with inflammatory responses and poor prognosis in multiple tumor types, including colon 21 . WISP genes are targets of Wnt-1, which are thought to contribute to tissue invasion in breast and colon cancer 22 . Our gene ontology enrichment analysis 15 of genes associated with hypervariable expression in blocks (false discovery rate <0.05) showed enrichment for categories including extracellular matrix remodeling genes ( Supplementary Table 13 ). One cautionary note raised by these findings is that treatment of cancer patients with nonspecific DNA methylation inhibitors could have unintended consequences in the activation of tumor-promoting genes in hypomethylated blocks. It is also important to note that although previous studies 23, 24 have shown large-region hypermethylation or no regional methylation change, this study is based on whole-genome bisulfite sequencing. Nevertheless, future studies are needed to show whether block hypomethylation is a feature of cancer epigenomes in general.
Small DMRs, although representing a relatively small fraction of the genome (0.3%), are numerous (10, 125) and frequently involve loss of boundaries of DNA methylation at the edge of CpG islands, shifting of DNA methylation boundaries or the creation of novel hypomethylated regions in CG-dense regions that are not canonical islands. These data underscore the importance of hypomethylated CpG island shores in cancer, as shores associated with hypomethylation and gene overexpression in cancer are enriched for cell cycle related genes, suggesting a role in the unregulated growth that characterizes cancer. We propose a model relating tissue-specific DMRs to the sites of methylation hypervariability in cancer. Normal pluripotency might require stochastic gene expression at some loci, allowing for differentiation along alternative pathways in response to external stimuli or even intrinsically. The epigenome could collaborate to create a permissive state by changing its physical configuration to relax the stringency of epigenetic marks, as variance increases away from the extremes, and a similar process may occur in cancer. One way is by altering LOCKs, LADs and/or blocks, which could involve a change in the chromatin packing density or proximity to the nuclear lamina. Similarly, subtle shifts in DNA methylation boundaries near CpG islands may drive normal chromatin organization and tissuespecific gene expression. Given the importance of boundary regions for both small DMRs and large blocks identified in this study, it will be important to focus future epigenetic investigations on the boundaries of blocks and CpG islands (shores) and on genetic or epigenetic changes in genes encoding factors that interact with them.
The increased methylation and expression variability in each cancer type is consistent with the potential selective value of increased epigenetic plasticity in a varying environment first suggested for evolution but applicable to the strong but variable selective forces under which a cancer grows, such as varying oxygen tension or metastasis to a distant site 25 . Thus, increased epigenetic heterogeneity in cancer at cDMRs (which we show are also tDMRs) could underlie the ability of cancer cells to adapt rapidly to changing environments, such as increased oxygen with neovascularization then decreased oxygen with necrosis, or metastasis to a new intercellular milieu.
ONLINE METHODS
Custom GoldenGate array design. We selected 151 cDMRs previously identified 4 , regions which are consistently differentially methylated in all 13 colon cancers studied by comprehensive high-throughput array based methylation (CHARM) analysis. Probes were designed around CpGs that showed consistent differences in CHARM while still passing Illumina's quality control metrics 7 ; the majority of probes were in CpG island shores (66%) 4 . Details are listed in the Supplementary Note. Sample preparation. Cryogenically stored freshly frozen samples were obtained from the Cooperative Human Tissue Network (National Cancer Institute (NCI)), the National Wilms' Tumor Study tissue bank and Johns Hopkins Hospital under an institutional review board-approved waiver of consent. In total, 290 samples were assayed, including cancers from colon (10) , lung (24) , breast (27) , thyroid (36) and kidney (Wilms') (25) with matched normal tissues to 111 of these 122 cancers along with 30 colon premalignant adenomas, 18 normal colon and 9 normal breast samples. Two small sections were taken from each sample (~0.5 cm × 0.5 cm × 0.2 cm): one for DNA purification and one for histopathology. A boardcertified oncology pathologist independently and blindly validated classification of all samples and quantified specific cellular subtypes and p53 status for tumor and normal specimens from colon and kidney. Samples were prepared according to the Illumina protocol. Details are listed in the Supplementary Note. Custom Illumina methylation array processing and analysis. We quantile normalized 27 separately the raw intensity data from the Cy5 and Cy3 channels representing methylated and unmethylated DNA, and methylation levels were calculated as (Cy5 intensity) / (Cy5 intensity + Cy3 intensity). We ruled out batch effects following previously described procedures 28 . We regressed age out of the methylation data by fitting a linear model and repeated the analysis ( Fig. 1) using age-corrected measurements and obtained almost identical results (Supplementary Fig. 4) .
We also performed a separate array-based copy number analysis on five colon tumors and normal samples alongside five Wilms' tumor samples and normal kidney samples. We used intensities from the total DNA channel (Cy3) corrected for spatial effects, quantile normalized and corrected for sequence effects 29 . The resulting log ratios and estimated copy number segments are shown in Supplementary Figure 5 . Details are listed in the Supplementary Note.
Whole-genome bisulfite sequencing. Bisulfite sequencing libraries were prepared using a previously described approach 30 . Three colon cancer samples and their matched normal mucosa, as well as two colon adenomas, were sequenced simultaneously in adjacent flow cells on the SOLiD 3+ platform, yielding 50 base pair reads; we aligned the 7.79 billion reads from eight runs ( Supplementary Fig. 19 and Supplementary Table 14 ). We used λ phage genome spike-ins to estimate bisulfite conversion rates, which all are between 99.7% and 99.8% (Supplementary Fig. 20 and Supplementary Table 14 ). Details are listed in the Supplementary Note. Capture bisulfite sequencing. Capture bisulfite libraries were prepared using previously developed Bisulfite Padlock Probes (BSPP) 31 on the same samples for which we performed whole-genome sequencing. The targeted regions were designed partly based on DMRs previously found in colon cancer 4 , as well as on tissue and promoter DMRs. We aligned the 79.3 million reads obtained from six samples ( Supplementary Fig. 21 and Supplementary Table 15 ). Details are listed in the Supplementary Note.
Alignment of sequencing reads from bisulfite-treated DNA. We developed an alignment tool for bisulfite-treated sequencing reads. We used a spacedseed index biased neither toward nor against methylated cytosines in CpGs. It extends the BSMAP 32 approach to allow alignment of SOLiD colorspace reads as well as Illumina reads (Supplementary Note) .
After alignment, we summarized CpG methylation evidence in unique alignments (Supplementary Tables 16-18 ). Evidence was filtered (Supplementary Note) based on M-bias plots (Supplementary Figs. 22,23) .
To measure global prevalence of non-CpG cytosine methylation, we examined nucleotide evidence overlapping non-CpG cytosine positions. The fraction of methylated evidence did not rise above the approximate fraction expected from unconverted cytosines ( Supplementary Table 19 ). We also examined for strand bias and found no significant evidence of it (Supplementary Tables 3,7,20,21) .
BSmooth: smoothing of bisulfite sequencing reads and DMR detection. The cornerstone of our analysis is a statistical approach that permits accurate and precise estimates of methylation values with 4× coverage data. The approach uses the unbiased alignment algorithm described previously and then averages data across neighboring CpGs and across biological samples to improve precision over naïve single-CpG and single-sample estimates. Biological replicates permitted us to parse cancer related differences from inter-individual variability (Supplementary Fig. 13 ). For each CpG, we obtained the number of methylated reads (M) and unmethylated reads (U) with coverage M + U = N. We assumed that for each CpG, M followed a binomial distribution with success probability (p) equal to the true methylation level and N trials. A naïve estimate of p is M/N. Inspired by CHARM 4 , we used local likelihood estimation 33 , which uses a binomial model to put greater weight on CpGs with high coverage. We assumed that p(L), the methylation level at location L, was a smooth function of L, meaning proximal CpGs had similar methylation levels 34 (Supplementary Fig. 24 ). We developed two related approaches, one using low-frequency smoothing for blocks and a high-frequency version for small DMRs (Supplementary Note). BSmooth was validated by comparison to a high-coverage capture bisulfite dataset (see below).
Obtaining blocks and small DMRs. We developed a method for finding blocks and small DMRs using t statistics based on the smoothed methylation data while accounting for biological variability (Supplementary Fig. 13 ). We estimated standard errors using only the normal samples because cancer samples were prone to high variability (Fig. 1) . In other words, we did not assume that the cancer samples were biological replicates. Blocks (lowfrequency smoothed methylation values) and small DMRs (high-frequency smoothed methylation values) were obtained based on these t statistics. We also computed sample-specific blocks using the same methodology comparing a single tumor sample to all three normal samples ( Supplementary  Tables 20,21 ). Details are listed in the Supplementary Note.
We determined that sample-specific blocks co-occur by observing that they are largely contained within the blocks from the joint analysis. We also performed a simulation analysis (Supplementary Note): for each chromosome, we used the observed distribution of the sample-specific blocks to estimate the distance between block starts and generated 1,000 simulated start positions according to this distribution (Supplementary Fig. 10) .
Small DMRs were classified based on methylation profiles of the tumor and normal samples within the DMR as well as the two 800-bp flanking regions (Supplementary Note).
Comparison of bisulfite capture and bisulfite pyrosequencing with wholegenome bisulfite sequencing. The capture bisulfite experiment provided data for 39,262 capture regions ranging from 230 bp to 2,200 bp. We only considered CpGs with coverage above 30×, which resulted in 39,285, 107,332 and 86,855 CpGs in the normal samples and 125,611, 94,320, and 104,680 in the cancers. We estimated methylation for each CpG without averaging across genomic regions or samples. We found excellent agreement between the capture bisulfite data and the high-frequency smoothed whole-genome bisulfite data, especially considering the experiments were performed in two different laboratories (Supplementary Fig. 8 ).
In addition, bisulfite pyrosequencing (primers are listed in Supplementary  Table 22 ) on the same six samples in the small DMR regions shown in Figure 3 showed good correspondence with our smoothed methylation values (Supplementary Fig. 9 ).
Assays for large organized chromatin K9-modifications (LOCKs).
ChIPon-chip H3K9Me2 experiments and microarray data analysis were performed as previously described 12 using primary human pulmonary fibroblasts at the second passage purchased from ScienCell.
